A Phase 1 interventional study of Human interferon alfa 1b inhalation solution and Human interferon alfa 1b inhalation solution placebo in Healthy Participants, sponsored by Kexing Biopharm Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by Kexing Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Randomized, Double-Blind, Placebo-Controlled Phase-I Clinical Study to Evaluate the Tolerability, Safety and PK Profiles of Human interferon alfa 1b inhalation solution in Healthy Adult Subjects after Administration of Single Ascending Doses and Multiple Ascending Doses
Primary objective:To evaluate the tolerability and safety of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects.
Secondary objectives: To evaluate the pharmacokinetic (PK) profiles of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects and to evaluate the immunogenicity of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects
Kexing Biopharm Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human interferon alfa 1b inhalation solution:200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups
Drug: Human interferon alfa 1b inhalation solution
Human interferon alfa 1b inhalation solution placebo :200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups
Drug: Human interferon alfa 1b inhalation solution placebo
Human interferon alfa 1b inhalation solution drug product:1,200,000 IU, and 1,80,000 IU dose groups
Drug: Human interferon alfa 1b inhalation solution
Human interferon alfa 1b inhalation solution placebo :1,200,000 IU, and 1,80,000 IU dose groups
Drug: Human interferon alfa 1b inhalation solution placebo
Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.
Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.
Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
TEAEs
The adverse events and incidence of treatment-emergent adverse events(TEAEs)
Time frame: Day 1 up to 29 or Day 1 up to 32
(ADRs)
The adverse events and incidence of adverse drug reactions (ADRs)
Time frame: Day 1 up to 29 or Day 1 up to 32
(SAE)
The adverse events and incidence of serious adverse events (SAE)
Time frame: Day 1 up to 29 or Day 1 up to 32
TEAEs that lead to subject discontinuation from the study
The adverse events and incidence of TEAEs that lead to subject discontinuation from the study
Time frame: Day 1 up to 29 or Day 1 up to 32
Cmax After a Single Dose of GB05 Drug Product
The maximum concentration (Cmax) of GB05 Drug Product
Time frame: Day 1 up to 3
Tmax After a Single Dose of GB05 Drug Product
The maximum concentration (Tmax) of GB05 Drug Product
Time frame: Day 1 up to 3
AUC0-t and AUC0-inf After a Single Dose of GB05 Drug Product
The area under the concentration-time curve (AUC0-t and AUC0-inf) of GB05 Drug Product.
Time frame: Day 1 up to 3
t1/2 After a Single Dose of GB05 Drug Product
The elimination half-life (t1/2) of GB05 Drug Product
Time frame: Day 1 up to 3
Ke After a Single Dose of GB05 Drug Product
The elimination rate constant (Ke) of GB05 Drug Product
Time frame: Day 1 up to 3
Vd After a Single Dose of GB05 Drug Product
The apparent distribution volume (Vd) of GB05 Drug Product.
Time frame: Day 1 up to 3
MRT After a Single Dose of GB05 Drug Product
The average residence time (MRT) of GB05 Drug Product
Time frame: Day 1 up to 3
CL After a Single Dose of GB05 Drug Product
The clearance rate (CL) of GB05 Drug Product
Time frame: Day 1 up to 3
Cmax,ss After Multiple Doses of GB05 Drug Product
The maximum concentration at steady state (Cmax,ss) of GB05 Drug Product
Time frame: Day 1 up to 10
Cmin,ss After Multiple Doses of GB05 Drug Product
The minimum concentration at steady state (Cmin,ss) of GB05 Drug Product
Time frame: Day 1 up to 10
Css_av After Multiple Doses of GB05 Drug Product
The average steady-state plasma concentration (Css_av) of GB05 Drug Product
Time frame: Day 1 up to 10
DF After Multiple Doses of GB05 Drug Product
The degree of fluctuation in the concentration during the dosing interval (DF) of GB05 Drug Product
Time frame: Day 1 up to 10
(Cmax,ss-Cmin,ss)/Cmin,ss After Multiple Doses of GB05 Drug Product
The fluctuation amplitude \[(Cmax,ss-Cmin,ss)/Cmin,ss\] of GB05 Drug Product
Time frame: Day 1 up to 10
ADA
The Number and Percentage of Participants of anti-drug antibody (ADA)
Time frame: Day 1 up to 29 or Day 1 up to 32
NAb
The Number and Percentage of Participants of neutralizing antibody (NAb).
Time frame: Day 1 up to 29 or Day 1 up to 32
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Apr 2023, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kexing Biopharm Co., Ltd.